{"brief_title": "A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer", "brief_summary": "This 2 arm study will compare the efficacy and safety of Taxotere + Xeloda, versus Taxotere alone, following a regimen of Adriamycin plus Cytoxan in women with high-risk breast cancer. Following 4 cycles of Adriamycin and Cytoxan, patients will be randomized to receive either 1)Taxotere 75mg/m2 iv on day 1 and Xeloda 825mg/m2 po bid on days 1-14 of each 3 week cycle or 2) Taxotere 100mg/m2 iv alone on day 1 of each 3 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is 500+ individuals.", "condition": "Breast Cancer", "intervention_type": "Drug", "intervention_name": "Taxotere", "description": "100mg/m2 iv on day 1 of each 3 week cycle", "arm_group_label": "2", "criteria": "Inclusion Criteria: - female patients 18-70 years of age; - adenocarcinoma of the breast; - previous invasive breast cancer if diagnosed >5 years before entering study; - no evidence of metastatic disease. Exclusion Criteria: - history of severe hypersensitivity reaction to Taxotere; - previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane; - treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years.", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "70 Years", "healthy_volunteers": "No", "id": "NCT00089479.xml"}